Related references
Note: Only part of the references are listed.Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer
Luisa Klemke et al.
CELL DEATH & DISEASE (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer
Maria Grzes et al.
CANCERS (2020)
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Eliran Kadosh et al.
NATURE (2020)
p53 tetramerization: at the center of the dominant-negative effect of mutant p53
Jovanka Gencel-Augusto et al.
GENES & DEVELOPMENT (2020)
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou et al.
MOLECULAR CANCER (2020)
IL-6 promotes endometrial cancer cells invasion and migration through signal transducers and activators of transcription 3 signaling pathway
Qi Che et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers
Zhe Ji et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1
Evangelia Loizou et al.
CANCER DISCOVERY (2019)
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Michael Orth et al.
RADIATION ONCOLOGY (2019)
Mutant p53 as a guardian of the cancer cell
Fiamma Mantovani et al.
CELL DEATH AND DIFFERENTIATION (2019)
Cancer therapeutic targeting using mutant-p53-specific siRNAs
Ifeoma Ubby et al.
ONCOGENE (2019)
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Kanaga Sabapathy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action
Bartosz Wawrzynow et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42
Gina L. Razidlo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Ramona Schulz-Heddergott et al.
CANCERS (2018)
Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics
Jacob M. Smigiel et al.
CANCERS (2018)
Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion
Ramona Schulz-Heddergott et al.
CANCER CELL (2018)
Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer
Nagaraj S. Nagathihalli et al.
CANCER RESEARCH (2018)
Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases
Yun Zhang et al.
NATURE COMMUNICATIONS (2018)
Complexes formed by mutant p53 and their roles in breast cancer
Arianna Bellazzo et al.
BREAST CANCER-TARGETS AND THERAPY (2018)
Mutant p53 partners in crime
Michael P. Kim et al.
CELL DEATH AND DIFFERENTIATION (2018)
p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
Evguenia M. Alexandrova et al.
CELL DEATH & DISEASE (2017)
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Jonas Cicenas et al.
CANCERS (2017)
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Cristoforo Grasso et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer
Junli Guo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
STAT3 as a potential therapeutic target in ALDI+ and CD44+/CD24+ stem cell-like pancreatic cancer cells
Li Lin et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Alejandro Parrales et al.
NATURE CELL BIOLOGY (2016)
Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells
Nagaraj S. Nagathihalli et al.
ONCOTARGET (2016)
Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer
Nagaraj S. Nagathihalli et al.
GASTROENTEROLOGY (2015)
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
E. M. Alexandrova et al.
NATURE (2015)
Oncostatin-M Differentially Regulates Mesenchymal and Proneural Signature Genes in Gliomas via STAT3 Signaling
Kumar Natesh et al.
NEOPLASIA (2015)
Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Michael Paul Kim et al.
FRONTIERS IN ONCOLOGY (2015)
Mutant p53: One, no One, and One Hundred Thousand
Dawid Walerych et al.
FRONTIERS IN ONCOLOGY (2015)
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Kodappully Sivaraman Siveen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
MicroRNA let-7 downregulates STAT3 phosphorylation cancer cells by increasing SOCS3 expression
Kripa Patel et al.
CANCER LETTERS (2014)
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo
Melanie Spitzner et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
H. Landmann et al.
CELL DEATH & DISEASE (2014)
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity
J. Xu et al.
CELL DEATH & DISEASE (2014)
Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer
Tomer Cooks et al.
CANCER CELL (2013)
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
W. Hanel et al.
CELL DEATH AND DIFFERENTIATION (2013)
Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma
Simon M. Denley et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
Rabih Said et al.
ONCOTARGET (2013)
SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells
M. Herreros-Villanueva et al.
ONCOGENESIS (2013)
Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo
Ming Kei Lee et al.
CANCER CELL (2012)
Mutant p53: one name, many proteins
William A. Freed-Pastor et al.
GENES & DEVELOPMENT (2012)
Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2
Milena Wiech et al.
PLOS ONE (2012)
APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1-STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival
Angelo A. Cardoso et al.
PLOS ONE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells
Li Lin et al.
CANCER RESEARCH (2011)
The role of mutant p53 in human cancer
Amanda M. Goh et al.
JOURNAL OF PATHOLOGY (2011)
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Sergei I. Grivennikov et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Mutant p53 Gain-of-Function in Cancer
Moshe Oren et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Mutant p53 Drives Invasion by Promoting Integrin Recycling
Patricia A. J. Muller et al.
CELL (2009)
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Maddalena Adorno et al.
CELL (2009)
Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions
D. Walerych et al.
ONCOGENE (2009)
Tumor Suppressive Functions of p53
Jack T. Zilfou et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
When mutants gain new powers: news from the mutant p53 field
Ran Brosh et al.
NATURE REVIEWS CANCER (2009)
Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor α in cancer cells
Lilach Weisz et al.
CANCER RESEARCH (2007)
Stattic: A small-molecule inhibitor of STAT3 activation and dimerization
Jochen Schust et al.
CHEMISTRY & BIOLOGY (2006)
Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation
Silvia Di Agostino et al.
CANCER CELL (2006)
Hsp90 chaperones wild-type p53 tumor suppressor protein
D Walerych et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
AN Bullock et al.
ONCOGENE (2000)